Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 23;8:748. doi: 10.3389/fbioe.2020.00748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Babajani, Soltani, Jamshidi, Farjoo and Niknejad.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Methods of cell delivery. (1) Intratumoral injection provides higher amounts of MSCs in the tumor microenvironment; however, impressive complications including infection, pain, and accessibility to deep tumors reduce the efficacy. (2) Intravenous and intra-arterial injection: (a) injection of MSCs to internal carotid artery results in accumulation of MSCs in brain tumors such as glioblastoma; (b) injection of MSCs in common carotid artery reduces the efficacy of cell delivery to glioma in comparison to internal carotid artery; (c) MSCs injected through the femoral vein enter cardiopulmonary circulation that reduces the efficacy of cell administration. Intravenous and intra-arterial injected MSCs cross the BBB to reach brain malignancies. (3) Intrathecal administration enables MSCs to access cerebrospinal fluid (CSF) and reach meningeal tumors. (4) Intranasal administration of MSCs as a novel method reduces complications of injection and provides MSCs in brain tumors. (5) Intraperitoneal injection of MSCs causes distribution in peritoneal cavity and can be used in ovarian malignancies. (6) Application of catheter-based cell delivery provides a safe pathway to deliver MSCs to deep organs and reduce the complication of direct injection.